Financials · NVCR

NovoCure Limited (NVCR) financials

For the twelve months ended Sep 30, 2026, NovoCure Limited reported $725.39M of revenue and -$121.73M of net income.

Revenue, TTM
$725.39M
Revenue growth, YoY
+12.9%
Net income, TTM
-$121.73M
Net margin
-16.8%
Free cash flow, TTM
-$24.61M
EPS, diluted, TTM
-$1.06
Cash
$96.73M
P/S
1.91
Market cap
$1.38B
Annual revenue$655.35M
FY2016FY2025
Annual net income-$136.23M
FY2016FY2025
Annual free cash flow-$75.68M
FY2016FY2025

NVCR revenue and earnings growth

NVCR revenueQ3 2026$193.40M

Quarter YoY
+15.7%
QoQ
+5.3%
FY YoY
+8.3%
5Y CAGR
+5.8%
10Y CAGR
+34.8%

NVCR revenue was $193.40M in fiscal Q3 2026 (ended Sep 30, 2026), up 15.7% from a year earlier and up 5.3% from the prior quarter. For the full fiscal 2025 it was $655.35M, up 8.3% from fiscal 2024. Compound annual growth was +5.8% over 5 years and +34.8% over 10 years. It rose in 9 of the last 10 fiscal years. Fiscal 2025 is the highest of the 13 fiscal years on file.

NVCR net incomeQ3 2026-$10.44M

NVCR net income was -$10.44M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$37.27M a year earlier. For the full fiscal 2025 it was -$136.23M, compared with -$168.63M in fiscal 2024.

NVCR EPSQ3 2026-$0.09

NVCR diluted EPS was -$0.09 in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$0.33 a year earlier. For the full fiscal 2025 it was -$1.22, compared with -$1.56 in fiscal 2024.

NVCR free cash flowQ3 2026$15.75M

Quarter YoY
+5.5%
QoQ
13x

NVCR free cash flow was $15.75M in fiscal Q3 2026 (ended Sep 30, 2026), up 5.5% from a year earlier and up about 13-fold from the prior quarter. For the full fiscal 2025 it was -$75.68M, compared with -$69.22M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 31, 2019
Dec 31, 2018
Dec 31, 2017
Dec 31, 2016
Revenue$655.35M$605.22M$509.34M$537.84M$535.03M$494.37M$351.32M$248.07M$177.03M$82.89M
Cost of revenue$166.88M$137.18M$128.28M$114.87M$114.88M$106.50M$88.61M$80.05M$55.61M$39.87M
Gross profit$488.47M$468.04M$381.06M$422.97M$420.15M$387.87M$262.71M$168.02M$121.42M$36.61M
Research and development$224.54M$209.65M$223.06M$206.09M$201.30M$132.01M$79.00M$50.57M$38.10M$41.47M
Selling, general and admin$177.67M$189.83M$164.06M$132.75M$126.13M$107.44M$87.95M$73.46M$59.11M$51.01M
Operating income-$153.80M-$170.50M-$232.87M-$89.52M-$44.33M$30.40M-$914.0K-$33.67M-$39.33M-$115.32M
Interest expense$22.22M$11.66M$4.91M$8.11M$8.84M$18.05M$14.64M$16.91M$11.69M$7.32M
Pre-tax income-$136.25M-$131.16M-$191.74M-$81.85M-$52.08M$18.10M-$8.82M-$45.94M-$48.50M-$121.46M
Income tax-$23.0K$37.47M$15.30M$10.69M$6.28M-$1.71M-$1.59M$17.62M$13.16M$10.38M
Net income-$136.23M-$168.63M-$207.04M-$92.53M-$58.35M$19.81M-$7.23M-$63.56M-$61.66M-$131.84M
EPS, basic-$1.22-$1.56-$1.95-$0.88-$0.56$0.20-$0.07-$0.69-$0.70-$1.54
EPS, diluted-$1.22-$1.56-$1.95-$0.88-$0.56$0.18-$0.07-$0.69-$0.70-$1.54
Diluted shares111.5M107.8M106.4M104.7M103.4M108.9M97.2M91.8M88.5M85.6M

Balance sheet

Balance sheet
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 31, 2019
Dec 31, 2018
Dec 31, 2017
Dec 31, 2016
Cash and equivalents$93.55M$166.09M$240.82M$115.83M$209.61M$246.17M$179.42M$142.76M$80.72M$100.05M
Receivables$89.44M$74.23M$61.22M$86.26M$93.57M$96.70M$58.86M$36.52M$29.57M$6.34M
Inventory$41.11M$35.09M$38.15M$29.38M$24.43M$27.42M$23.70M$22.55M$22.02M$25.55M
Current assets$646.73M$1.11B$1.03B$1.11B$1.07B$999.44M$439.95M$321.37M$245.13M$261.87M
Total assets$804.33M$1.24B$1.15B$1.19B$1.14B$1.05B$479.45M$339.79M$265.30M$282.08M
Current liabilities$223.23M$756.39M$179.12M$158.78M$142.60M$113.61M$86.31M$64.56M$50.20M$36.88M
Short-term debt$0---------
Long-term debt$195.05M$97.30M$568.82M$565.51M$562.22M$429.90M$149.42M$149.27M$97.34M$96.23M
Total debt$195.05M$97.30M$568.82M$565.51M$562.22M$429.90M$149.42M$149.27M$97.34M$96.23M
Total liabilities$463.86M$880.61M$783.63M$750.48M$729.00M$575.46M$261.66M$227.53M$151.73M$139.74M
Shareholders' equity$340.47M$360.18M$362.50M$441.17M$410.49M$476.53M$217.79M$112.26M$113.56M$142.34M

Cash flow

Cash flow
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 31, 2019
Dec 31, 2018
Dec 31, 2017
Dec 31, 2016
Operating cash flow-$49.03M-$26.37M-$73.34M$30.79M$82.76M$99.15M$26.62M-$1.86M-$33.13M-$107.59M
Capital expenditures$26.65M$42.85M$27.09M$21.36M$24.17M$14.97M$10.48M$6.71M$7.37M$5.67M
Free cash flow-$75.68M-$69.22M-$100.43M$9.43M$58.59M$84.18M$16.14M-$8.58M-$40.50M-$113.27M
Investing cash flow$437.28M-$140.24M$184.15M-$139.96M-$144.83M-$472.85M-$51.67M-$5.49M$8.63M$13.00M
Financing cash flow-$451.34M$90.31M$15.79M$15.49M$25.70M$440.21M$61.68M$69.37M$5.17M$75.12M
Dividends paid--------$0$0
Stock-based compensation$104.83M$160.03M$115.61M$106.95M$94.90M$75.72M$52.42M$39.85M$27.12M$22.14M
Depreciation and amortization$14.65M$11.23M$10.97M$10.62M$10.25M$9.15M$8.46M$9.01M$7.68M$5.65M

Key ratios

Key ratios
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 31, 2019
Dec 31, 2018
Dec 31, 2017
Dec 31, 2016
Revenue growth, YoY8.3%18.8%-5.3%0.5%8.2%40.7%41.6%40.1%113.6%150.5%
Gross margin74.5%77.3%74.8%78.6%78.5%78.5%74.8%67.7%68.6%44.2%
Operating margin-23.5%-28.2%-45.7%-16.6%-8.3%6.1%-0.3%-13.6%-22.2%-139.1%
Net margin-20.8%-27.9%-40.6%-17.2%-10.9%4.0%-2.1%-25.6%-34.8%-159.1%
Free cash flow margin-11.5%-11.4%-19.7%1.8%11.0%17.0%4.6%-3.5%-22.9%-136.6%
Return on equity-40.0%-46.8%-57.1%-21.0%-14.2%4.2%-3.3%-56.6%-54.3%-92.6%
Return on assets-16.9%-13.6%-18.1%-7.8%-5.1%1.9%-1.5%-18.7%-23.2%-46.7%
Current ratio2.901.465.787.007.538.805.104.984.887.10
Debt to equity0.570.271.571.281.370.900.691.330.860.68

Source: XBRL data NovoCure Limited files with the SEC, latest filing dated Oct 29, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

NVCR peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
NVCR$725.39M+12.9%-$121.73M-16.8%$1.38B
SYK$26.30B+7.9%$3.62B13.8%$117.88B
MMM$25.25B+1.7%$3.54B14.0%$94.90B
BSX$21.07B+8.9%$3.50B16.6%$64.27B
BDX$23.25B+17.4%$941.00M4.0%$59.39B
MDLN$30.68B-$683.00M2.2%$51.92B
RMD$5.73B+9.0%$1.59B27.8%$33.69B
DXCM$5.10B+13.0%$991.00M19.4%$31.08B
WST$3.40B+12.6%$638.90M18.8%$29.01B

NVCR FAQ

9 questions
  • What is NVCR revenue?
    NovoCure Limited (NVCR) reported $725.39M of revenue for the twelve months ended Sep 30, 2026. That is up 12.9% from the year before. Revenue for fiscal 2025 was $655.35M.
  • Is NVCR profitable?
    No. NovoCure Limited reported a net loss of $121.73M for the twelve months ended Sep 30, 2026.
  • How much cash and debt does NVCR have?
    NovoCure Limited reported $96.73M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • How fast is NVCR revenue growing?
    NovoCure Limited's revenue changed +8.3% in fiscal 2025, to $655.35M. Its compound annual growth rate was +5.8% over 5 years and +34.8% over 10 years.
  • What is NVCR gross margin?
    NovoCure Limited's gross profit was $558.67M on $725.39M of revenue for the twelve months ended Sep 30, 2026, a gross margin of 77.0%.
  • What is NVCR free cash flow?
    NovoCure Limited generated -$24.61M of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of -$722.0K less capital expenditures.
  • What is NVCR earnings per share?
    Diluted earnings per share were -$1.06 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.
  • When did NVCR last report financial results?
    The latest statements here come from NovoCure Limited's 10-Q filed on Oct 29, 2026, covering the period ended Sep 30, 2026.
  • Where does this NVCR financial data come from?
    Quantisnow builds these statements from the structured XBRL data NovoCure Limited files with the SEC. It is provided for information only and is not investment advice.